Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir.

Humans Graft vs Host Disease / prevention & control Hematopoietic Stem Cell Transplantation Cyclophosphamide / therapeutic use Transplantation, Homologous Cytomegalovirus Infections

Journal

Bone marrow transplantation

ISSN: 1476-5365

Titre abrégé: Bone Marrow Transplant

Pays: England

ID NLM: 8702459

Informations de publication

Date de publication:
10 2023

Historique:

received: 04 04 2023

accepted: 13 07 2023

revised: 28 06 2023

medline: 9 10 2023

pubmed: 20 7 2023

entrez: 19 7 2023

Statut: ppublish

Résumé

Cytomegalovirus (CMV) reactivations are strong stimulators of immune-reconstitution (IR) in hematopoietic stem cell transplantation (HSCT) recipients. Herein, we analyzed 317 CMV-seropositive consecutive patients (n = 109 letermovir, LTV; n = 208 no-LTV), undergoing HSCT with post-transplant cyclophosphamide (PTCy) and calcineurin inhibitor- (CNI) free graft-versus-host-disease (GvHD) prophylaxis. At day+90, median CD19

Identifiants

DOI: 10.1038/s41409-023-02046-9 PMID: 37468541

pubmed: 37468541

doi: 10.1038/s41409-023-02046-9

pii: 10.1038/s41409-023-02046-9

doi:

Substances chimiques

letermovir 1H09Y5WO1F

Cyclophosphamide 8N3DW7272P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

1104-1111

Informations de copyright

Références

Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.

doi: 10.1016/j.bbmt.2008.03.005

Kanakry CG, Tsai HL, Bolanos-Meade J, Smith BD, Gojo I, Kanakry JA, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124:3817–27.

pubmed: 25316679 pmcid: 4263989 doi: 10.1182/blood-2014-07-587477

Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96:27–35.

pubmed: 25703164 doi: 10.1111/ejh.12541

Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, et al. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transpl. 2015;21:906–12.

doi: 10.1016/j.bbmt.2015.01.026

Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transpl. 2015;21:941–4.

doi: 10.1016/j.bbmt.2015.01.020

Greco R, Lorentino F, Morelli M, Giglio F, Mannina D, Assanelli A, et al. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood. 2016;128:1528–31.

pubmed: 27495140 doi: 10.1182/blood-2016-06-723205

Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S, et al. Posttransplantation cyclophosphamide- and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant. Transpl Cell Ther. 2021;27:776 e1–e13.

doi: 10.1016/j.jtct.2021.05.023

Cordonnier C, Ljungman P, Cesaro S, Hirsch HH, Maschmeyer G, von Lilienfeld-Toal M, et al. The EHA research roadmap: infections in hematology. Hemasphere. 2021;5:e662.

pubmed: 34877477 pmcid: 8639104 doi: 10.1097/HS9.0000000000000662

Greco R, Ciceri F, Noviello M, Bondanza A, Vago L, Oliveira G, et al. Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transpl. 2018;53:1201–5.

doi: 10.1038/s41409-018-0167-8

Greco R, Hoogenboom JD, Bonneville EF, Anagnostopoulos A, Cuoghi A, Dalle JH, et al. Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transpl. 2023;58:1–4.

Oltolini C, Greco R, Galli L, Clerici D, Lorentino F, Xue E, et al. Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA matching. Biol Blood Marrow Transpl. 2020;26:1179–88.

doi: 10.1016/j.bbmt.2020.01.013

Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, et al. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica. 2022;107:857–67.

pubmed: 33832208 doi: 10.3324/haematol.2020.271445

Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021;137:3291–305.

pubmed: 33657221 pmcid: 8351903 doi: 10.1182/blood.2020009362

Gimenez E, Torres I, Albert E, Pinana JL, Hernandez-Boluda JC, Solano C, et al. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. Am J Transpl. 2019;19:2479–94.

doi: 10.1111/ajt.15515

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.

pubmed: 29211658 doi: 10.1056/NEJMoa1706640

Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. Transpl Infect Dis. 2019;21:e13187.

pubmed: 31585500 pmcid: 8573720 doi: 10.1111/tid.13187

Lin A, Flynn J, DeRespiris L, Figgins B, Griffin M, Lau C, et al. Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Transpl Cell Ther. 2021;27:85 e1–e6.

doi: 10.1016/j.bbmt.2020.10.009

Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transpl. 2021;56:853–62.

doi: 10.1038/s41409-020-01082-z

Robin C, Thiebaut A, Alain S, Sicre de Fontbrune F, Berceanu A, D'Aveni M, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the french compassionate program. Biol Blood Marrow Transpl. 2020;26:978–84.

doi: 10.1016/j.bbmt.2020.01.027

Sharma P, Gakhar N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, et al. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transpl. 2020;55:780–6.

doi: 10.1038/s41409-019-0730-y

Lorentino F, Xue E, Mastaglio S, Giglio F, Clerici D, Farina F, et al. Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation. Blood Adv. 2022;6:3053–7.

pubmed: 35078219 pmcid: 9131907 doi: 10.1182/bloodadvances.2021006213

Su Y, Stern A, Karantoni E, Nawar T, Han G, Zavras P, et al. Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study. Clin Infect Dis. 2022;75:795–804.

pubmed: 34979021 pmcid: 9477449 doi: 10.1093/cid/ciab1064

Sperotto A, Candoni A, Gottardi M, Facchin G, Stella R, De Marchi R, et al. Cytomegalovirus prophylaxis versus pre-emptive strategy: different CD4(+) and CD8(+) T cell reconstitution after allogeneic hematopoietic stem cell transplantation. Transpl Cell Ther. 2021;27:518 e1–e4.

doi: 10.1016/j.jtct.2021.03.003

Gabanti E, Borsani O, Colombo AA, Zavaglio F, Binaschi L, Caldera D, et al. Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis. Transpl Cell Ther. 2022;28:211 e1–e9.

doi: 10.1016/j.jtct.2022.01.008

Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood 2021;138:34–43.

pubmed: 33657225 pmcid: 8493975 doi: 10.1182/blood.2020009396

Huntley D, Talaya A, Gimenez E, Martinez A, Hernandez-Boluda JC, Hernani R, et al. Features of cytomegalovirus DNAemia blips in allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies. Biol Blood Marrow Transpl. 2020;26:972–7.

doi: 10.1016/j.bbmt.2020.01.015

Cassaniti I, Colombo AA, Bernasconi P, Malagola M, Russo D, Iori AP, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transpl. 2021;21:1622–8.

doi: 10.1111/ajt.16450

Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transpl. 2020;20:1703–11.

doi: 10.1111/ajt.15764

Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.

pubmed: 27682069 doi: 10.1093/cid/ciw668

Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295–304.

pubmed: 4153799 doi: 10.1097/00007890-197410000-00001

Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64.

pubmed: 9217189 doi: 10.1046/j.1365-2141.1997.1112925.x

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transpl. 2016;22:4–10.

doi: 10.1016/j.bbmt.2015.09.001

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401.e1.

doi: 10.1016/j.bbmt.2014.12.001

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.

doi: 10.1016/j.bbmt.2009.07.004

Gagelmann N, Kroger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021? Haematologica. 2021;106:1794–804.

pubmed: 33730842 pmcid: 8252938 doi: 10.3324/haematol.2020.268839

Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia. 2015;29:396–405.

pubmed: 24897508 doi: 10.1038/leu.2014.180

Duong A, Sweet A, Jain R, Hill JA, Pergam SA, Boeckh M, et al. Clinically significant drug interaction: letermovir and voriconazole. J Antimicrob Chemother. 2020;75:775–7.

pubmed: 31800049 doi: 10.1093/jac/dkz499

Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2006;12:552–9.

doi: 10.1016/j.bbmt.2005.12.032

Greco R, Barbanti MC, Lupo Stranghellini MT, Giglio F, Morelli M, Messina C, et al. Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 2016;51:1022–4.

doi: 10.1038/bmt.2016.112

Mfarrej B, Gaude J, Couquiaud J, Calmels B, Chabannon C, Lemarie C. Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products. Cytotherapy. 2021;23:77–87.

pubmed: 32718876 doi: 10.1016/j.jcyt.2020.06.005

McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, et al. Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil. J Clin Pharm. 2019;59:1331–9.

doi: 10.1002/jcph.1423

Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, et al. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood. 2013;122:1963–73.

pubmed: 23777765 doi: 10.1182/blood-2012-12-470872

Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, et al. Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection. PLoS One. 2013;8:e61841.

pubmed: 23596528 pmcid: 3626592 doi: 10.1371/journal.pone.0061841

Itzykson R, Robin M, Moins-Teisserenc H, Delord M, Busson M, Xhaard A, et al. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica. 2015;100:114–23.

pubmed: 25261095 pmcid: 4281324 doi: 10.3324/haematol.2014.113415

Olkinuora H, von Willebrand E, Kantele JM, Vainio O, Talvensaari K, Saarinen-Pihkala U, et al. The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol. 2011;73:586–93.

pubmed: 21323694 doi: 10.1111/j.1365-3083.2011.02530.x

Lugthart G, van Ostaijen-Ten Dam MM, Jol-van der Zijde CM, van Holten TC, Kester MG, Heemskerk MH, et al. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2014;20:655–61.

doi: 10.1016/j.bbmt.2014.01.018

Rashidi A, Luo X, Cooley S, Anasetti C, Waller EK, Brunstein CG, et al. The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. Blood Adv. 2019;3:2465–9.

pubmed: 31427278 pmcid: 6712525 doi: 10.1182/bloodadvances.2019000298

von Niederhausern V, Ruder J, Ghraichy M, Jelcic I, Muller AM, Schanz U, et al. B-cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9:e200027.

doi: 10.1212/NXI.0000000000200027

Della Chiesa M, Falco M, Muccio L, Bertaina A, Locatelli F, Moretta A. Impact of HCMV infection on NK cell development and function after HSCT. Front Immunol. 2013;4:458.

pubmed: 24379818 pmcid: 3861788

Basílio-Queirós D, Venturini L, Luther-Wolf S, Dammann E, Ganser A, Stadler M, et al. Adaptive NK cells undergo a dynamic modulation in response to human cytomegalovirus and recruit T cells in in vitro migration assays. Bone Marrow Transpl. 2022;57:712–20.

doi: 10.1038/s41409-022-01603-y

Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E. Human NK cells can control CMV infection in the absence of T cells. Blood. 2008;112:914–5.

pubmed: 18650467 doi: 10.1182/blood-2008-05-157354

Jin F, Lin H, Gao S, Wang H, Yan H, Guo J, et al. Characterization of IFNγ-producing natural killer cells induced by cytomegalovirus reactivation after haploidentical hematopoietic stem cell transplantation. Oncotarget. 2017;8:51–63.

pubmed: 27980216 doi: 10.18632/oncotarget.13916

Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF, et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2009;15:315–25.

doi: 10.1016/j.bbmt.2008.11.030

Muccio L, Bertaina A, Falco M, Pende D, Meazza R, Lopez-Botet M, et al. Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica 2016;101:371–81.

pubmed: 26659918 pmcid: 4815729 doi: 10.3324/haematol.2015.134155

Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131:247–62.

pubmed: 28986344 pmcid: 5757695 doi: 10.1182/blood-2017-05-780668

Rambaldi B, Kim HT, Reynolds C, Chamling Rai S, Arihara Y, Kubo T, et al. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021;5:352–64.

pubmed: 33496734 pmcid: 7839379 doi: 10.1182/bloodadvances.2020003005

Zaghi E, Calvi M, Puccio S, Spata G, Terzoli S, Peano C, et al. Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT. JCI Insight. 2021;6:e146973.

pubmed: 34003794 pmcid: 8262468 doi: 10.1172/jci.insight.146973